biOasis Technologies Inc. to Present at the 1st Annual Neuroscience BioPartnering and Investment Forum in New York on February 23, 2016

VANCOUVER, BC--(Marketwired - February 11, 2016) - BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it will be presenting at the 1^st Annual Neuroscience Biopartnering and Investment Forum in New York on February 23, 2016. A focus of the forum is on neurodegenerative and orphan diseases, areas where the biOasis BBB technology has shown significant potential.

biOasis has also been asked to participate in the panel discussion on Rare and Orphan Diseases at the conference. This panel will be led by Dr. Mark Day from Alexion Pharmaceuticals. Dr. Reinhard Gabathuler, Chief Scientist at biOasis, will be participating in the panel discussion and will be presenting the latest developments regarding the biOasis Transcend technology. 

Rob Hutchison, biOasis CEO, stated, "We are very happy to participate in this panel discussion as biOasis has a significant focus in the area of Rare Disease, both in addressing the delivery to the brain of traditional therapies such as enzymes to treat Lysosomal Storage Diseases, and also within the emerging field of gene therapy. In both cases the biOasis technology, Transcend, can play a major role in enabling these treatments to reach the brain in therapeutic doses, which has not been achieved previously. This will assist in treating the CNS or brain complications of many dreadful diseases." 

ForumAgenda: http://www.sachsforum.com/uploads/5/1/9/6/51964431/nbpi1_final_agenda_v.3.pdf

About Transcend

Transcend is biOasis' proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.